Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | PPARG | P37231 | 2/20 | 0.58 |
| ▸ | PPARA | Q07869 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21103699 | 0.92 | CYP1A2 (0.53) | KMT2AHPGDCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL21991450 | 0.92 | CYP1A2 (0.53) | KMT2AHPGDCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL21991248 | 0.88 | CYP1A2 (0.49) | KMT2AHPGDCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL21991482 | 0.86 | HPGD (0.60) | KMT2AHPGDCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL21991517 | 0.85 | KMT2A (0.56) | KMT2AHPGDCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL27912406 | 0.84 | HPGD (0.65) | KMT2AHPGDCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL21992473 | 0.84 | NPC1 (0.54) | KMT2AHPGDCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10703205 | 0.84 | EPHX2 (0.59) | KMT2AHPGDCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11462507 | 0.84 | EPHX2 (0.50) | KMT2ACYP1A2CYP2C9CYP2C19PPARG | |
| SCHEMBL8638497 | 0.83 | HPGD (0.59) | KMT2AHPGDCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220304957-A1 | ANTI-CANCER COMPOSITIONS AND METHODS OF USE | UNIV LOUISIANA STATE (US) | 2022-09-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | KMT2A 4842/4885HPGD 765/4885CYP1A2 2919/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | KMT2A 4842/4885HPGD 765/4885CYP1A2 2919/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | KMT2A 4842/4885HPGD 765/4885CYP1A2 2919/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | KMT2A 4842/4885HPGD 765/4885CYP1A2 2919/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | KMT2A 4842/4885HPGD 765/4885CYP1A2 2919/4885 |
| US-20220304957-A1 | ANTI-CANCER COMPOSITIONS AND METHODS OF USE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, MCL1 | KMT2A 2060/4885HPGD 1564/4885CYP1A2 3362/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | KMT2A 4842/4885HPGD 765/4885CYP1A2 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.